Predictive therapeutic marker of bevacizumab against patients with ovarian cancer
Not Applicable
- Conditions
- Advanced ovarian cancerOvarian cancer
- Registration Number
- JPRN-jRCT1031180427
- Lead Sponsor
- Hirakawa Takashi
- Brief Summary
This clinical trial was aimed to searching for biomarkers in patients treated with bevacizumab for advanced ovarian cancer. The enrollment was discontinued due to avoidance of bevacizumab-specific adverse events and a change in treatment strategy due to the introduction of new drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 2
Inclusion Criteria
1) Pathologically confirmed advanced ovarian cancer with stage III/IV
2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
3) Patient with evaluable lesion based on RECIST
4) Written informed consent
Exclusion Criteria
1) Pregnant woman
2) Patients with double primary cancer or serious infectious disease requiring antibiotic therapy
3) Other cases attending physician it is determined unsuitable for registration of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changing of SUVmax, MTV and TLG, and the efficacy of bevacizumab<br>Evaluation after 1 month from administ ration of bevacizumab<br>Exploratory investigation of many biomarkers using blood sample
- Secondary Outcome Measures
Name Time Method